On October 10, 2019, Chambers' hosted its first forum in China. Dubbed “Chambers Forum: Shanghai 2019”, and held in Shanghai, the event drew participants including law firm partners, business executives and companies' general counsels to discuss major legal and business issues impacting China and its neighboring markets. Jingtian & Gongcheng was invited to host "Coexistence of Challenges and Opportunities"—China Legal Practice Seminar on Life Sciences, exchanging ideas on challenges and opportunities for China's life sciences industry with over 50 professionals including business executives and general counsels. Jingtian & Gongcheng's Partners, including Zhou Hanshuo, Ren Wei and Zhao Ye, served as speakers for the forum.
Jingtian & Gongcheng provides one-stop, end-to-end legal services in the life sciences sector, including proposals on industrial regulation and business compliance, technology licensing, product registration, channel and commercial development, advertising and marketing, medical data management and standardization, intellectual property planning, protection and defense, anti- competition and anti-monopoly in the operation of life science enterprises, greenfield investment, investment and financing, M&A and restructuring, domestic and overseas listing, bond issuance and restructuring of life science enterprises, as well as dispute resolution and compliance defense within the industry.
Our industry experience spans across a wide range of sub-sectors, including health care and public health, pharmaceuticals, biotechnology, medical devices, detection and diagnosis, medical software and technology, senior care and health care management. Our representative projects include the listing of mainland China’s first hospital operator—Phoenix Healthcare, the synchronous listing of Asia's largest hospital operator—IHH in Singapore and Malaysia, the listing of China’s first medical service company—Concord Medical on the New York Stock Exchange, the listing of Chinese biomedical unicorn—WuXi Biologics in Hong Kong, the listing of the first IVD enterprise—IVD Medical in Hong Kong, the listing of Chimin on the A-share market, and the listing (approval from the CSRC) of BrightGene on the Science and Technology Innovation Board.
